Evanthia T. Roussos-Torres

Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.

Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.

Adopting an alternative structure for clinical trials in immunotherapy.

Clocking cancer: the circadian clock as a target in cancer therapy.

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.

Evaluating the impact of age on immune checkpoint therapy biomarkers.

Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.

Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.

Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.